Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal change.
Alzheimer disease (AD) biomarkers reflect specific features of AD pathology. These biomarkers may be used in the diagnosis and staging of AD, or may act as surrogate end points in clinical trials. Thus, a thorough understanding of the diagnostic accuracy of and longitudinal change in cerebrospinal fluid and MrI AD biomarkers is important.
Department of Neurology and Alzheimer Center, Vrije Universiteit Medical Center, Boelelaan 1117, Amsterdam, The Netherlands. nd.prins@vumc.nl
Niels D
ND
Prins
John C
JC
van Swieten
D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000473:pathology*; D015415:Biomarkers / Q000134:cerebrospinal fluid*; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000592:standards*; D015203:Reproducibility of Results
D015415:Biomarkers